Christopher K. Scott - 11 Feb 2022 Form 4 Insider Report for IRADIMED CORP (IRMD)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
11 Feb 2022, 20:34:38 UTC
Prior SEC filing
09 Dec 2021
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Christopher K. Scott

Key filing fact

Christopher K. Scott filed Form 4 for IRADIMED CORP (IRMD) on 11 Feb 2022.

Key facts

  • This page summarizes Christopher K. Scott's Form 4 filing for IRADIMED CORP (IRMD).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 11 Feb 2022, 20:34.

Change

  • Previous filing in this sequence was filed on 09 Dec 2021.
  • Current net transaction value: -$965,424.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IRMD transaction

Common Stock

Sale

Transaction value
$965,424
Shares
-19,286
Change %
-58%
Price
$50.06
Shares after
13,710
Date
11 Feb 2022
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This transaction was executed in multiple trades at prices ranging from $50.00 to $50.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and priced at which the transaction was effected.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .